Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Τίτλος | Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Pentheroudakis, G., Mavroeidis L., Papadopoulou K., Koliou G-A., Bamia C., Chatzopoulos K., Samantas E., Mauri D., Efstratiou I., Pectasides D., Makatsoris T., Bafaloukos D., Papakostas P., Papatsibas G., Bombolaki I., Chrisafi S., Kourea H. P., Petraki K., Kafiri G., Fountzilas G., & Kotoula V. |
Journal | Clin Colorectal Cancer |
Volume | 18 |
Issue | 4 |
Pagination | e370-e384 |
Date Published | 2019 12 |
ISSN | 1938-0674 |
Λέξεις κλειδιά | Aged, Alternative Splicing, Angiogenesis Inducing Agents, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biomarkers, Tumor, Camptothecin, Capecitabine, Colorectal Neoplasms, Drug Resistance, Neoplasm, Female, Fluorouracil, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Irinotecan, Leucovorin, Male, Middle Aged, Oxaliplatin, Prognosis, Prospective Studies, Protein Isoforms, Retrospective Studies, Survival Rate, Vascular Endothelial Growth Factor A |
Abstract | BACKGROUND: Alternative splicing of vascular endothelial growth factor A (VEGFA) results in VEGFAxxxb antiangiogenic isoforms that fail to activate angiogenesis. Bevacizumab, widely used in patients with metastatic colorectal cancer (CRC), binds both VEGFA and VEGFAxxxb isoforms. |
DOI | 10.1016/j.clcc.2019.07.007 |
Alternate Journal | Clin Colorectal Cancer |
PubMed ID | 31402291 |